Print

Purpose

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will either be studied as: - Monotherapy, or - Combination therapy: - epcoritamab + venetoclax - epcoritamab + lenalidomide - epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin®) and prednisone). The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (SLL) and patients with Richter's Syndrome (RS). Study participants with R/R CLL/SLL are treated either with epcoritamab as monotherapy or epcoritamab + venetoclax. Study participants with RS are treated either with epcoritamab as monotherapy or epcoritamab + lenalidomide or epcoritamab + R-CHOP. The trial consists of two parts, a dose-escalation phase (phase Ib) and an expansion phase (phase II). Patients with RS are only included in the expansion phase. Epcoritamab will be injected subcutaneously (under the skin). Standard-of-care and combination treatments (venetoclax, lenalidomide, and R-CHOP) will be given either orally (by mouth) or intravenously (in a vein). Study details include: - Study duration will be up to 5 years. - The treatment duration for each participant will be between 18 months (1.5 years) and 24 months (2 years), depending upon the treatment arm assigned. - The visit frequency will be either weekly, every other week, or monthly, depending upon the part of the study. All participants will receive active drug; no one will be given placebo.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 2. Evidence of CD20 positivity in a sample representative of the disease at Screening. 3. Acceptable hematology parameters and organ function based on baseline bloodwork. 4. For R/R CLL arms - Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria. 5. For R/R CLL arms - Received at least 2 prior lines of systemic anti-neoplastic therapy including a Bruton's tyrosine kinase (BTK) inhibitor. 6. For all RS arms - Have tumor biopsy-proven CD20+ Diffuse large B-cell Lymphoma (DLBCL) and a clinical history of CLL/SLL. 7. For all RS arms - Must have measurable disease by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) or magnetic resonance imaging (MRI) scan. 8. For all RS arms - Must provide mandatory formalin-fixed, paraffin-embedded (FFPE) tumor biopsy sample. 9. Life expectancy >3 months on standard of care (SOC). 10. For RS - monotherapy arm: Deemed as ineligible for chemoimmunotherapy at investigator's discretion or participant who refuses to receive intensive chemotherapy 11. For RS - lenalidomide combination therapy arm - Deemed as ineligible for chemoimmunotherapy at the investigator's discretion, or participant who refuses to receive intensive chemotherapy. - Eligible for treatment with lenalidomide. - Must be willing to use contraception and adhere to the Lenalidomide Pregnancy Risk Minimization Plan 12. For RS - R-CHOP combination Therapy Arm - - Eligible for treatment with R-CHOP. 13. For R/R CLL - venetoclax combination Therapy arm - after receiving at least 1 prior line of systemic antineoplastic therapy.

Exclusion Criteria

  1. Received prior treatment with a CD3×CD20 bispecific antibody. 2. Received any prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. 3. Received (CAR) T-cell therapy within 100 days or an investigational drug within 4 weeks, prior to first dose of epcoritamab. 4. Autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy. 5. Received vaccination with live vaccines within 28 days. 6. Clinically significant cardiac disease. 7. Known current malignancy other than inclusion diagnosis. 8. Has had major surgery within 4 weeks. 9. Active hepatitis B virus or active hepatitis C. 10. Known history of HIV. 11. For R/R CLL arms - Any history of RS or evidence indicating a potential Richter's transformation. 12. Received venetoclax within 24 months prior to beginning venetoclax ramp-up for this trial and progressed on treatment. 13. For all RS arms - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia. 14. RS - Lenalidomide Combination Therapy and RS Monotherapy Arms - received more than 2 prior lines of therapy for RS. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Epcoritamab in R/R CLL/SLL 		In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
  • Biological: Epcoritamab
    Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
    Other names:
    • EPKINLY™
    • GEN3013
    • DuoBody®-CD3xCD20
Experimental
Epcoritamab in RS 		Only in expansion phase.
  • Biological: Epcoritamab
    Epcoritamab will be administered subcutaneously in cycles of 28 days.
    Other names:
    • EPKINLY™
    • GEN3013
    • DuoBody®-CD3xCD20
Experimental
Epcoritamab + Venetoclax in R/R CLL/SLL 		In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.
  • Biological: Epcoritamab
    Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
    Other names:
    • EPKINLY™
    • GEN3013
    • DuoBody®-CD3xCD20
  • Drug: Venetoclax
    Venetoclax tablets will be administered orally once daily during the 5-week ramp up period and during Cycle 1-26 of 28 or 35 days each.
Experimental
Epcoritamab + Lenalidomide in RS 		Only in expansion phase.
  • Biological: Epcoritamab
    Epcoritamab will be administered subcutaneously in cycles of 28 days.
    Other names:
    • EPKINLY™
    • GEN3013
    • DuoBody®-CD3xCD20
  • Drug: Lenalidomide
    Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days up to 12 cycles.
Experimental
Epcoritamab + R-CHOP in RS 		Only in expansion phase.
  • Biological: Epcoritamab
    Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.
    Other names:
    • EPKINLY™
    • GEN3013
    • DuoBody®-CD3xCD20
  • Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
    R-CHOP will be administered intravenously in cycles of 21 days for the first 6 cycles.

Recruiting Locations

O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama 35233

More Details

Status
Recruiting
Sponsor
Genmab

Study Contact

Genmab Trial Information
+4570202728
clinicaltrials@genmab.com

Detailed Description

The purpose of the dose-escalation phase of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL. The purpose of the expansion phase is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab + venetoclax at the RP2D for patients with R/R CLL/SLL. Along with this, epcoritamab monotherapy, epcoritamab + lenalidomide and epcoritamab + R-CHOP will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.